Journal article
Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence
- Abstract:
- Cellular senescence is an irreversible side effect of some pharmaceuticals which can contribute to tissue degeneration.To determine whether pharmaceutical glucocorticoids induce senescence in tenocytes.Features of senescence (β-galactosidase activity at pH 6 (SA-β-gal) and active mammalian/mechanistic target of rapamycin (mTOR) in cell cycle arrest) as well as the activity of the two main pathways leading to cell senescence were examined in glucocorticoid-treated primary human tenocytes. Evidence of senescence-inducing pathway induction in vivo was obtained using immunohistochemistry on tendon biopsy specimens taken before and 7 weeks after subacromial Depo-Medrone injection.Dexamethasone treatment of tenocytes resulted in an increased percentage of SA-βgal-positive cells. Levels of phosphorylated p70S6K did not decrease with glucocorticoid treatment indicating mTOR remained active. Increased levels of acetylated p53 as well as increased RNA levels of its pro-senescence effector p21 were evident in dexamethasone-treated tenocytes. Levels of the p53 deacetylase sirtuin 1 were lower in dexamethasone-treated cells compared with controls. Knockdown of p53 or inhibition of p53 activity prevented dexamethasone-induced senescence. Activation of sirtuin 1 either by exogenous overexpression or by treatment with resveratrol or low glucose prevented dexamethasone-induced senescence. Immunohistochemical analysis of tendon biopsies taken before and after glucocorticoid injection revealed a significant increase in the percentage of p53-positive cells (p=0.03). The percentage of p21-positive cells also tended to be higher post-injection (p=0.06) suggesting glucocorticoids activate the p53/p21 senescence-inducing pathway in vivo as well as in vitro.As cell senescence is irreversible in vivo, glucocorticoid-induced senescence may result in long-term degenerative changes in tendon tissue.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 5.2MB, Terms of use)
-
- Publisher copy:
- 10.1136/annrheumdis-2012-203146
Authors
- Publisher:
- BMJ Publishing Group
- Journal:
- Annals of the rheumatic diseases More from this journal
- Volume:
- 73
- Issue:
- 7
- Pages:
- 1405-1413
- Publication date:
- 2014-01-01
- Acceptance date:
- 2013-05-07
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
- Language:
-
English
- Keywords:
-
- Pubs id:
-
pubs:401925
- UUID:
-
uuid:22a35877-66c3-4807-9a3d-a653e5e8696b
- Local pid:
-
pubs:401925
- Source identifiers:
-
401925
- Deposit date:
-
2013-11-16
Terms of use
- Copyright holder:
- Poulsen et al
- Copyright date:
- 2014
- Notes:
- This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
If you are the owner of this record, you can report an update to it here: Report update to this record